Printer Friendly

SYNERGEN AND INSITE VISION ANNOUNCE COOPERATIVE AGREEMENT TO EVALUATE ANTRIL FOR OPHTHALMIC APPLICATIONS

 SYNERGEN AND INSITE VISION ANNOUNCE COOPERATIVE AGREEMENT TO
 EVALUATE ANTRIL FOR OPHTHALMIC APPLICATIONS
 ALAMEDA, Calif., Jan. 27 /PRNewswire/ -- Synergen Inc. (NASDAQ: SYGN) and InSite Vision Inc. announced today the signing of an agreement for joint evaluation of Synergen's ANTRIL(TM) (interleukin-1 receptor antagonist) in ocular inflammation. Safety and efficacy of ANTRIL in the eye will be evaluated in both pre- clinical and clinical studies. If the results of these preliminary studies are favorable, InSite will formulate ANTRIL in its proprietary polymeric delivery system for topical application to the eye. InSite's delivery vehicle has been shown to provide enhanced stability and duration of action for high-molecular weight proteins. Commercial terms for the development of ANTRIL as well as other potential Synergen compounds for the ophthalmic market are under discussion.
 Synergen is currently investigating ANTRIL in clinical trials for sepsis syndrome, rheumatoid arthritis, asthma, inflammatory bowel disease, graft-versus-host disease, chronic myelogenous leukemia and cachexia.
 Synergen is a 10-year old biopharmaceutical company engaged in the discovery, development and manufacture of protein-based pharmaceuticals. The company is focused on products to treat inflammatory diseases, slow and non-healing wounds and neurological disorders using recombinant DNA technology and the latest advances in molecular and cellular biology.
 InSite Vision is an ophthalmic company founded in 1986 to commercialize patented delivery technology and novel drug compounds with the goal of preserving and improving sight. InSite currently has four proprietary formulations in clinical trials for the treatment of inflammation, glaucoma and dry eye.
 -0- 1/27/92
 /CONTACT: Christa Nicholas of InSite Vision, 510-865-8800; or Debra Catz Bannister of Synergen, 303-938-6242/
 (SYGN) CO: Insite Vision Inc.; Synergen Inc. ST: California, Colorado IN: MTC SU:


BB -- DV002 -- 3537 01/27/92 08:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:283
Previous Article:ROBERT GREENBERG RESIGNS AS L.A. GEAR CHAIRMAN & CHIEF EXECUTIVE OFFICER; SUCCEEDED BY STANLEY P. GOLD
Next Article:COMMODORE REPORTS SECOND FISCAL QUARTER RESULTS
Topics:


Related Articles
SYNERGEN TO BEGIN THREE NEW CLINICAL TRIALS
SYNERGEN AND UNIVERSITY OF COLORADO AWARDED BROAD PATENT FOR INTERLEUKIN-1 RECEPTOR ANTAGONIST
SYNERGEN INITIATES PHASE III TRIAL FOR ANTRIL
SYNERGEN APPOINTS DIRECTOR OF QUALITY
SYNERGEN ANNOUNCES NEW OFFICER AND MANAGEMENT APPOINTMENTS
SYNERGEN DEDICATES NEW COMMERCIAL-SCALE MANUFACTURING PLANT
SYNERGEN COMPLETES PHASE III CLINICAL TRIAL ENROLLMENT FOR ANTRIL IN SEPSIS; 900 PATIENTS RECRUITED IN THE U.S., CANADA AND EUROPE
NEW SYNERGEN SEPSIS TRIAL ENROLLS FIRST PATIENT; FOLLOW-UP TRIAL IN SEVERE SEPSIS PATIENTS BEGINS ON SCHEDULE
SYNERGEN FILES EUROPEAN MARKETING APPLICATION FOR ANTRIL IN SEVERE SEPSIS
AMGEN SETTLES SUIT AGAINST SUBSIDIARY.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters